A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
Latest Information Update: 14 May 2025
At a glance
- Drugs KIN-3248 (Primary)
- Indications Carcinoma; Cholangiocarcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Kinnate Biopharma
Most Recent Events
- 07 May 2025 Status changed from active, no longer recruiting to discontinued.
- 30 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2023 Trial design presented at the 48th European Society for Medical Oncology Congress.